Overall, the data indicate that the unique and interacting effects of the different IFN families, as well as IFN-independent mechanisms, have distinct contributions to clinical endotypes, disease activity, and transcriptional pathways dysregulated in SLE, thereby explaining disease heterogeneity in this complex disease. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.